- Molecules
- 38
MedsAcross lists 38 molecules linked to Non-small-cell lung carcinoma, each with brands, manufacturers and supply from India for licensed hospitals and physicians.
Medicines used
Molecules linked to this condition in public data. The prescriber decides which treatment is right.
- DocetaxelMicrotubule Inhibitor14 presentations6 brandsL01CD02
- PaclitaxelOrphanMicrotubule Inhibitor10 presentations8 brandsL01CD01
- CarboplatinPlatinum-based Drug6 presentations1 brandL01XA02
- GemcitabineNucleoside Metabolic Inhibitor13 presentations2 brandsL01BC05
- ErlotinibKinase Inhibitor3 presentations1 brandL01EB02
- IrinotecanOrphanTopoisomerase Inhibitor8 presentations3 brandsL01CE02
- PemetrexedOrphanFolate Analog Metabolic Inhibitor9 presentations8 brandsL01BA04
- CisplatinPlatinum-based Drug5 presentations1 brandL01XA01
- HydroxyureaOrphanAntimetabolite10 presentations6 brandsL01XX05
- DenosumabOrphanRANK Ligand Inhibitor21 presentations48 brandsM05BX04
- BevacizumabOrphanVascular Endothelial Growth Factor Inhibitor13 presentations17 brandsL01FG01
- TopotecanTopoisomerase Inhibitor5 presentations5 brandsL01CE01
- SelpercatinibOrphanKinase Inhibitor6 presentations2 brandsL01EX22
- AfatinibOrphanKinase Inhibitor6 presentations2 brandsL01XE13
- GefitinibOrphanKinase Inhibitor2 presentations2 brandsL01XE02
- CrizotinibOrphanKinase Inhibitor5 presentations2 brandsL01ED01
- BrigatinibOrphanKinase Inhibitor4 presentations2 brandsL01XE43
- NivolumabOrphanProgrammed Death Receptor-1 Blocking Antibody4 presentations2 brandsL01FF01
- VinorelbineVinca Alkaloid2 presentationsL01CA04
- DabrafenibOrphanKinase Inhibitor3 presentations3 brandsL01EC02
- DacomitinibOrphan3 presentations2 brandsL01EB07
- EntrectinibOrphan3 presentations2 brandsL01EX14
- LorlatinibOrphanKinase Inhibitor2 presentations2 brandsL01ED05
- OsimertinibOrphanKinase Inhibitor2 presentations2 brandsL01EB04
- RepotrectinibOrphanKinase Inhibitor2 presentations2 brandsL01EX28
- LazertinibKinase Inhibitor2 presentations2 brandsL01EB09
- AtezolizumabOrphanAntibodies2 presentations2 brandsL01FF05
- CapmatinibOrphanKinase Inhibitor2 presentations2 brandsL01EX17
- CetuximabOrphanEpidermal Growth Factor Receptor Antagonist2 presentations2 brandsL01FE01
- Ensartinib2 presentations1 brand
- IpilimumabOrphanCTLA-4-directed Blocking Antibody2 presentations2 brandsL01FX04
- RamucirumabOrphanVascular Endothelial Growth Factor Receptor 2 Antagonist2 presentations2 brandsL01FG02
- PembrolizumabOrphanProgrammed Death Receptor-1 Blocking Antibody1 presentation1 brandL01FF02
- TepotinibOrphanKinase Inhibitor1 presentation2 brandsL01EX21
- AlectinibOrphanKinase Inhibitor1 presentation2 brandsL01ED03
- AvelumabOrphanAntibodies1 presentation2 brandsL01FF04
- CeritinibOrphanKinase Inhibitor1 presentation2 brandsL01XE28
- TrametinibOrphan2 brandsL01EE01
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Need a medicine for Non-small-cell lung carcinoma?
Physicians and hospitals can request named-patient supply. We guide you through the documents your country requires.